A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Ruxolitinib
Related studies linked through entity extraction aliases.
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
- Status
- RECRUITING
- Phase
- PHASE2
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
- Status
- RECRUITING
- Phase
- PHASE1
JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
- Status
- RECRUITING
- Phase
- PHASE1
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
- Status
- RECRUITING
- Phase
- PHASE1
PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity
- Status
- RECRUITING
- Phase
- PHASE2
Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
- Status
- RECRUITING
- Phase
- PHASE3
MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Status
- RECRUITING
- Phase
- PHASE1
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
- Status
- RECRUITING
- Phase
- PHASE1
JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Status
- RECRUITING
- Phase
- PHASE2